![]() ![]() ![]() ![]() ![]() | Xplor-NIH home Documentation |
Next: Files “parallhdg.pro" and “topallhdg.pro" Up: Topology and Parameter Files Previous: Files “toph19.chromo" and “param19.chromo"
Files “parhcsdx.pro" and “tophcsdx.pro" for
Crystallographic Refinement (Polar Hydrogens)
This force field was
developed by Engh and Huber (1991).
It is a replacement for the “toph19x.pro" and “param19x.pro"
files that were used in previous versions of
X-PLOR. Inconsistencies for a number of residues have been removed,
which results in improved geometry and ![$R$](img6.png)
It was necessary to modify a number of improper and dihedral parameters compared to the “toph19.pro" and “param19.pro" files. The twofold dihedral angle term for peptide bonds was replaced by a onefold term with a large energy constant. When using the original twofold term, transitions of peptide bonds from trans to cis conformations occurred at high simulated annealing temperatures. In the case of X-Pro peptide bonds, the twofold term was retained, but with an increased energy constant. To facilitate transitions between trans and cis prolines, the user should lower this energy constant with the atom-based parameter statement:
parameter dihedral ( name CA and resname * ) ( name C and resname * ) ( name N and resname PRO ) ( name CA and resname PRO ) 5. 2 180. endThe energy constants of the improper torsion angle that specify the chirality of
![$C^{\alpha}$](img53.png)
For crystallographic refinement, it is reasonable to reduce or delete the charges on charged residues, such as Lys, Arg, or Glu. To modify the charges, one can use the vector statement (Section 2.16); e.g.,
vector do ( charge=0.0 ) ( resname LYS and ( name ce or name nz or name hz* ) ) {* Turn off charges for LYS.*} vector do ( charge=0.0 ) ( resname GLU and ( name cg or name cd or name oe* ) ) {* Turn off charges for GLU.*} vector do ( charge=0.0 ) ( resname ASP and ( name cb or name cg or name od* ) ) {* Turn off charges for ASP.*} vector do ( charge=0.0 ) ( resname ARG and ( name cd or name *E or name cz or name NH* or name HH* )
Xplor-NIH 2024-09-13